Stocks swung back down Wednesday after more signs piled up of the economic damage being caused by the coronavirus outbreak.

Markets have been stuck cycling between fear and budding optimism in recent weeks as investors try to guess how long and deep the looming recession will be, with the switch often flipping overnight or even within the same day. Economists have been slashing their forecasts in preparation for what they say may be the worst downturn since the Great Depression, but several reports that came out Wednesday were even more dismal than expected.

Retail sales sank a record 8.7% last month as lockdowns around the country to slow the spread of the virus closed stores and kept people at home. A separate survey of business conditions for manufacturers in New York state plunged to its lowest level in history, by a wide margin. Industrial production across the country also failed to meet economists’ already low expectations.

Stocks around the world and Treasury yields were already down in early Wednesday trading, and their drops accelerated after the release of the reports. Lower yields are a sign that demand for relatively safe investments like U.S. government bonds is increasing.

The S&P 500 was down 2.4% after the first half-hour of trading. The Dow Jones Industrial Average fell 494 points, or 2.1%, to 23,455, and the Nasdaq was down 1.9%.

Energy stocks took the sharpest losses after oil prices plunged to another 18-year low. Those in the S&P 500 index fell 5.8%.

Demand for oil around the world will fall this year by a record amount, the International Energy Agency said Wednesday. Benchmark U.S. crude touched its lowest price since 2002 before recovering slightly to $20.14 a barrel, little changed from a day earlier. Brent crude, the international standard, fell $1.27 to $28.30.

Earlier, the International Monetary Fund said this year's global economic output will shrink by 3%, a bigger loss than 2009's 0.1% decline during the financial crisis. That was a sharp reversal from the Fund's January forecast of 3.3% growth before the virus prompted governments to shut down factories, travel and other industries.

“The IMF forecast a deep economic winter," said Hayaki Narita of Mizuho Bank in a report. Narita said.

In Europe, London's FTSE 100 lost 2.5%, and the DAX in Frankfurt declined 3.2%. The CAC 40 in France retreated 2.9% to 4,437. The Nikkei 225 in Tokyo declined 0.5%, and Hong Kong's Hang Seng was off 1.2%.

Investors are focusing on how and when authorities may begin to ease business shutdowns and limits on people’s movements imposed to slow the spread of the coronavirus. The S&P 500 had jumped 3.1% just a day earlier in hopes that the outbreak was leveling off in some hotspots and could lead to parts of the economy opening back up.

U.S. President Donald Trump has been discussing how to roll back federal social distancing recommendations. U.S. governors are collaborating on plans to reopen their economies in what is likely to be a gradual process to prevent the coronavirus from rebounding.

China has reopened factories, shops and other businesses after declaring victory over the outbreak but forecasters say it will take months for industries to return to normal output, while exporters will face depressed global demand.

___

AP Business Writer Joe McDonald contributed.

Share:
More In Business
McDonald's Posts Q4 Earnings Miss; McPlant Burger Takes Off
McDonald's missed on both the top and bottom lines in its Q4 earnings, marking the fourth loss for the fast-food giant in the past eight quarters. It comes as higher costs from food to wages ate into the blue-chip company's profits. George Seay, CEO of investment advisor Annandale Capital, joined Wake Up with Cheddar to discuss the recent numbers and the better-than-expected success of the McPlant burger made with plant-based Beyond Meat. "They're changing with the times, and they have to," Seay noted. "You can just sell a Big Mac to everybody. There's a lot of people who don't want to eat a Big Mac anymore."
Moderna's Chief Medical Officer on Omicron Booster Trial, Annual Shots
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
Load More